The Association of the British Pharmaceutical Industry (ABPI) has said that the new 10-year plan for the NHS has underplayed ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

ASCO 2025 may be over, but the insights for the future of oncology are only just beginning. At the American Society of ...

The 7th Exosome-Based Therapeutics Development Summit with never-before-seen data, covering the end-to-end from discovery ...

The first half of 2025 has been marked by a surge in strategic activity across the global healthcare, life sciences, and ...

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...

Returning as the industry’s definitive forum from early discovery to clinical development, the 8th Annual TPD & Induced ...

After months of preparation and a drip-feed of some of its key features, the UK government has raised the curtain on its new ...

Fruzaqla was licensed by Takeda from China's Hutchmed for $400 million upfront in 2023 and has also been approved in the US ...

Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...

The CGM is based on magnetohydrodynamic (MHD) technology, which non-invasively samples interstitial fluid, the body fluid ...